Shares of Montage Gold Corp. (CVE:MAU – Get Free Report) have been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is C$3.27.
MAU has been the topic of several recent research reports. National Bankshares set a C$2.50 price target on Montage Gold and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. Ventum Cap Mkts raised Montage Gold to a “strong-buy” rating in a research note on Friday, September 27th. BMO Capital Markets lifted their target price on Montage Gold from C$3.00 to C$3.75 in a research note on Friday, October 25th. Cormark lifted their target price on Montage Gold from C$2.00 to C$2.50 in a research note on Thursday, August 15th. Finally, National Bank Financial raised Montage Gold to a “strong-buy” rating in a research note on Monday, July 22nd.
Read Our Latest Research Report on MAU
Montage Gold Trading Down 2.4 %
Montage Gold (CVE:MAU – Get Free Report) last announced its quarterly earnings results on Thursday, August 22nd. The company reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.01) by C($0.02). Equities research analysts expect that Montage Gold will post -0.04 EPS for the current year.
Montage Gold Company Profile
Montage Gold Corp., a precious metals exploration and development company, engages in the exploration and development of mineral properties. Its flagship property is the Koné Gold Project covering an area of 2,259 square kilometers located in the Côte d'Ivoire, West Africa. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Read More
- Five stocks we like better than Montage Gold
- Using the MarketBeat Dividend Yield Calculator
- Intel: Is Now the Time to Be Brave?
- What Investors Need to Know About Upcoming IPOs
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Special Dividend?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Montage Gold Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Montage Gold and related companies with MarketBeat.com's FREE daily email newsletter.